GlobeNewswire: Emergent Biosolutions, Inc. Contains the last 10 of 301 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:27:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853976/0/en/Emergent-BioSolutions-Continues-to-Broaden-Access-Awareness-and-Availability-of-NARCAN-Nasal-Spray-to-Help-Save-Lives-from-the-Ongoing-Opioid-Crisis.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis2024-03-28T12:15:03Z<![CDATA[GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported over 107,000 overdose deaths – a number that has risen almost every year and which has continued to break annual records.1 This includes a rise in synthetic opioid overdoses mainly driven by fentanyl.1 There is an inherent risk of potential overdose, wherever opioids are present, which has tragically become the leading cause of accidental death in the U.S.2 These statistics only further underscore the need for multi-sectoral action to address and prevent opioid overdose deaths.]]>https://www.globenewswire.com/news-release/2024/03/25/2851589/0/en/Emergent-BioSolutions-Receives-NAI-Status-for-Baltimore-Bayview-Manufacturing-Facility.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility2024-03-25T12:05:00Z<![CDATA[GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).]]>https://www.globenewswire.com/news-release/2024/03/06/2841810/0/en/Emergent-BioSolutions-Reports-Fourth-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results2024-03-06T21:31:00Z<![CDATA[GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/29/2837808/0/en/Emergent-BioSolutions-to-Release-Fourth-Quarter-Full-Year-2023-Financial-Results-and-Conduct-Conference-Call-on-March-6-2024.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 20242024-02-29T12:00:00Z<![CDATA[GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.]]>https://www.globenewswire.com/news-release/2024/02/21/2832608/0/en/Emergent-BioSolutions-Appoints-Industry-Leader-Joseph-C-Papa-as-New-President-and-CEO.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO2024-02-21T12:00:00Z<![CDATA[GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.]]>https://www.globenewswire.com/news-release/2024/01/11/2807893/0/en/Emergent-BioSolutions-Awarded-Procurement-Contract-Valued-up-to-235-8-Million-to-Supply-BioThrax-Anthrax-Vaccine-Adsorbed-to-the-U-S-Department-of-Defense.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense2024-01-11T13:00:00Z<![CDATA[GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033.]]>https://www.globenewswire.com/news-release/2024/01/09/2806181/0/en/Emergent-BioSolutions-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference-on-January-11-2024.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 20242024-01-09T12:30:00Z<![CDATA[GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.]]>https://www.globenewswire.com/news-release/2023/11/28/2786779/0/en/Emergent-BioSolutions-Receives-75-Million-Contract-Option-from-BARDA-to-Procure-Doses-of-CYFENDUS-Anthrax-Vaccine-Adsorbed-Adjuvanted.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)2023-11-28T11:59:00Z<![CDATA[GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and be complete by the end of the first quarter of 2024.]]>https://www.globenewswire.com/news-release/2023/11/24/2785559/0/en/Emergent-BioSolutions-Receives-NYSE-Notice-Regarding-Delayed-Form-10-Q-Filing.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing2023-11-24T12:30:00Z<![CDATA[GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC). Notices are routinely issued by the NYSE in such situations.]]>https://www.globenewswire.com/news-release/2023/11/08/2776840/0/en/Emergent-BioSolutions-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=23791Emergent BioSolutions Reports Third Quarter 2023 Financial Results2023-11-08T22:38:16Z<![CDATA[GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financial results reported include limited third quarter and year-to-date results, as well as selected balance sheet and cash flow information. As part of our quarterly review process, the Company determined that its state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the income tax benefits reflected on the Company’s income statement. While these non-cash items do not have any impact on the Company’s liquidity, cash flow, historical management compensation or covenant compliance, we have concluded that it is appropriate to delay the disclosure of full third quarter and year-to-date earnings information and the filing of our Quarterly Report on Form 10-Q for the period ended September 30, 2023 while we work to correct our prior period financial statements. We expect to complete this work in the near future.]]>